LIVIVO - Search results -

Search results

Result 1 - 10 of total 132

Search options

Article ; Online: The HOPE4MCI study: A randomized double-blind assessment of AGB101 for the treatment of MCI due to AD.

Mohs, Richard / Bakker, Arnold / Rosenzweig-Lipson, Sharon / Rosenblum, Michael / Barton, Russell L / Albert, Marilyn S / Cohen, Sharon / Zeger, Scott / Gallagher, Michela

Alzheimer's & dementia (New York, N. Y.)

2024 Volume 10, Issue 1, Page(s) e12446

Abstract: Introduction: In addition to the accumulation of amyloid plaques and neurofibrillary tangles, the presence of excess neural activity is a pathological hallmark of Alzheimer's disease (AD) and a prognostic indicator for progression of AD pathology and ... ...

Abstract	Introduction: In addition to the accumulation of amyloid plaques and neurofibrillary tangles, the presence of excess neural activity is a pathological hallmark of Alzheimer's disease (AD) and a prognostic indicator for progression of AD pathology and clinical/cognitive worsening in mild cognitive impairment due to Alzheimer's disease (MCI due to AD). The HOPE4MCI clinical study tested the efficacy of a therapeutic with demonstrated ability to normalize heightened neural activity in the hippocampus in a randomized controlled trial of 78 weeks duration in patients with MCI due to AD. Methods: One hundred and sixty-four participants were randomized to placebo ( Results: The mean change in CDR-SB was estimated to be 1.12 (95% confidence interval [CI]: 0.66, 1.69) for the AGB101 arm and 1.22 (95% CI: 0.75, 1.78) for the placebo arm. The estimated difference between arms is -0.10 (95% CI: -0.85, 0.58), which was not statistically significant. In a prespecified analysis, the difference was -0.45 (95% CI: -1.43, 0.53) for ApoE-4 noncarriers and -0.10 (95% CI: -0.92, 0.72) for apolipoprotein E (ApoE)-4 carriers. Discussion: The possibility that ApoE-4 carriers and noncarriers will respond differently to therapeutic intervention is consistent with recently reported findings from biologics and the present results show further testing of AGB101 in patients with MCI due to AD who are noncarriers of the ApoeE-4 allele is warranted. Conclusions from the HOPE4MCI study are limited primarily due to the small sample size and results can only be regarded as a guide to future research.
Language	English
Publishing date	2024-01-24
Publishing country	United States
Document type	Journal Article
ZDB-ID	2832891-7
ISSN	2352-8737 ; 2352-8737
ISSN (online)	2352-8737
ISSN	2352-8737
DOI	10.1002/trc2.12446
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article ; Online: Heart health meets cognitive health: evidence on the role of blood pressure.

Palta, Priya / Albert, Marilyn S / Gottesman, Rebecca F

The Lancet. Neurology

2021 Volume 20, Issue 10, Page(s) 854–867

Abstract: The enormous societal and financial burden of Alzheimer's disease and related dementias requires the identification of risk factors and pathways to reduce dementia risk. Blood pressure (BP) management and control is one promising area, in which data have ...

Abstract	The enormous societal and financial burden of Alzheimer's disease and related dementias requires the identification of risk factors and pathways to reduce dementia risk. Blood pressure (BP) management and control is one promising area, in which data have been inconclusive. Accumulating evidence over the past 5 years shows the effectiveness of BP management interventions among older individuals at risk, most notably from the SPRINT-MIND trial. These findings have been coupled with longitudinal observational data. However, to date, the results do not concur on the optimal timing and target of BP lowering, and further study in diverse populations is needed. Given the long preclinical phase of dementia and data supporting the importance of BP control earlier in the lifecourse, long-term interventional and observational studies in ethnically and racially diverse populations, with novel imaging and blood-based biomarkers of neurodegeneration and vascular cognitive impairment to understand the pathophysiology, are needed to advance the field.
MeSH term(s)	Biomarkers ; Blood Pressure/physiology ; Cognition/physiology ; Cognitive Dysfunction/metabolism ; Cognitive Dysfunction/physiopathology ; Disease Progression ; Heart/physiology ; Heart Diseases/metabolism ; Heart Diseases/physiopathology ; Humans
Chemical Substances	Biomarkers
Language	English
Publishing date	2021-09-29
Publishing country	England
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Review
ZDB-ID	2081241-3
ISSN	1474-4465 ; 1474-4422
ISSN (online)	1474-4465
ISSN	1474-4422
DOI	10.1016/S1474-4422(21)00248-9
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5955: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Book ; Conference proceedings: Biomarkers of Preclinical Alzheimer's Disease

Albert, Marilyn S

2016

Abstract: CIT): The purpose of the symposium is to inform and provide an update for the broader National Institutes of Health community on recent advances in the development of biomarkers for detecting and tracking preclinical Alzheimer's disease at the earliest ... ...

Institution	National Institute on Aging,
Event/congress	Biomarkers of Preclinical Alzheimer's Disease (Symposium) (2016, BethesdaMd.)
Author's details	National Institute on Aging, NIH
Abstract	(CIT): The purpose of the symposium is to inform and provide an update for the broader National Institutes of Health community on recent advances in the development of biomarkers for detecting and tracking preclinical Alzheimer's disease at the earliest stage of the disease process. Speakers will discuss blood and CSF biomarkers, insights from PET imaging of brain amyloid burden, recent advances in PET tau imaging and the application of molecular imaging to clinical trials.
MeSH term(s)	Alzheimer Disease/diagnosis ; Biomarkers
Language	English
Size	1 online resource (1 streaming video file (5 hr., 44 min.)) :, color, sound
Document type	Book ; Conference proceedings
Note	Closed-captioned.
Database	Catalogue of the US National Library of Medicine (NLM)

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾

Book: Geriatric neuropsychology

Albert, Marilyn S.

1988

Author's details	ed. by Marilyn S. Albert
Keywords	Nervous System Diseases / in old age ; Neuropsychology / in old age ; Alterspsychiatrie ; Neuropsychologie ; Alter
Subject	Alter Mensch ; Betagter ; Senioren ; Senior ; Altenpsychiatrie ; Alter ; Geriatrische Psychiatrie ; Gerontopsychiatrie ; Psychogeriatrie
Size	XIV, 316 S. : Ill., graph. Darst.
Edition	1. print
Publisher	Guilford
Publishing place	New York u.a.
Publishing country	United States
Document type	Book
HBZ-ID	HT003297061
ISBN	0-89862-722-2 ; 978-0-89862-722-0
Database	Catalogue ZB MED Medicine, Health

In stock of ZB MED Cologne/Königswinter

Shelf mark	Loan status	Location
1989 A 2079	order for loan	Magazin

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Test-retest reliability of 3D velocity-selective arterial spin labeling for detecting normal variations of cerebral blood flow.

Xu, Feng / Liu, Dapeng / Zhu, Dan / Hillis, Argye E / Bakker, Arnold / Soldan, Anja / Albert, Marilyn S / Lin, Doris D M / Qin, Qin

NeuroImage

2023 Volume 271, Page(s) 120039

Abstract: Velocity-selective inversion (VSI) based velocity-selective arterial spin labeling (VSASL) has been developed to measure cerebral blood flow (CBF) with low susceptibility to the prolonged arterial transit time and high sensitivity to brain perfusion ... ...

Abstract	Velocity-selective inversion (VSI) based velocity-selective arterial spin labeling (VSASL) has been developed to measure cerebral blood flow (CBF) with low susceptibility to the prolonged arterial transit time and high sensitivity to brain perfusion signal. The purpose of this magnetic resonance imaging study is to evaluate the test-retest reliability of a VSI-prepared 3D VSASL protocol with whole-brain coverage to detect baseline CBF variations among cognitively normal participants in different brain regions. Coefficients of variation (CoV) of both absolute and relative CBF across scans or sessions, subjects, and gray matter regions were calculated, and corresponding intraclass correlation coefficients (ICC) were computed. The higher between-subject CoV of absolute CBF (13.4 ± 2.0%) over within-subject CoV (within-session: 3.8 ± 1.1%; between-session: 4.9 ± 0.9%) yielded moderate to excellent ICC (within-session: 0.88±0.08; between-session: 0.77±0.14) to detect normal variations of individual CBF. The higher between-region CoV of relative CBF (11.4 ± 3.0%) over within-region CoV (within-session: 2.3 ± 0.9%; between-session: 3.3 ± 1.0%) yielded excellent ICC (within-session: 0.92±0.06; between-session: 0.85±0.12) to detect normal variations of regional CBF. Age, blood pressure, end-tidal CO
MeSH term(s)	Humans ; Spin Labels ; Reproducibility of Results ; Arteries ; Magnetic Resonance Imaging/methods ; Cerebrovascular Circulation/physiology
Chemical Substances	Spin Labels
Language	English
Publishing date	2023-03-16
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural
ZDB-ID	1147767-2
ISSN	1095-9572 ; 1053-8119
ISSN (online)	1095-9572
ISSN	1053-8119
DOI	10.1016/j.neuroimage.2023.120039
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3664: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 7: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: CSF Alzheimer Disease Biomarkers: Time-Varying Relationships With MCI Symptom Onset and Associations With Age, Sex, and

Greenberg, Barry D / Pettigrew, Corinne / Soldan, Anja / Wang, Jiangxia / Wang, Mei-Cheng / Darrow, Jacqueline A / Albert, Marilyn S / Moghekar, Abhay

Neurology

2023 Volume 99, Issue 15, Page(s) e1640–e1650

Abstract: Background and objectives: This study aimed to examine whether baseline CSF measures of Alzheimer disease (AD)-related pathology are associated with the time to onset of mild cognitive impairment (MCI) and whether these associations differ by age, sex, ! ...

Abstract	Background and objectives: This study aimed to examine whether baseline CSF measures of Alzheimer disease (AD)-related pathology are associated with the time to onset of mild cognitive impairment (MCI) and whether these associations differ by age, sex, Methods: Measures of amyloid (Aβ1-42 and Aβ1-40), phospho-tau (ptau181), and total tau (t-tau) were determined from CSF samples obtained at baseline from participants in an ongoing longitudinal project, known as the Biomarkers for Older Controls at Risk for Alzheimer Disease study (BIOCARD) study. The fully automated, Lumipulse G immunoassay was used to analyze the specimens. Cox regression models were used to examine the relationship of baseline biomarker levels with time to symptom onset of MCI and interactions with age, sex, and Results: Analyses included 273 participants from the BIOCARD cohort, who were cognitively normal and predominantly middle-aged at baseline, and have been followed for an average of 16 years (max = 23.6). During follow-up, 94 progressed to MCI (median time to symptom onset = 6.9 years). In Cox regression models, elevated ptau181 and t-tau levels were associated with time to MCI symptom onset if it occurred within 7 years of baseline (HR 1.386 and 1.329; Discussion: The lengthy follow-up of BIOCARD participants permitted an examination of time-varying associations between CSF AD biomarkers with MCI symptom onset and the influence of sex, baseline age, and
MeSH term(s)	Alzheimer Disease/pathology ; Amyloid beta-Peptides ; Apolipoprotein E4/genetics ; Biomarkers ; Cognitive Dysfunction/diagnosis ; Female ; Humans ; Male ; Middle Aged ; Peptide Fragments ; tau Proteins
Chemical Substances	Amyloid beta-Peptides ; Apolipoprotein E4 ; Biomarkers ; Peptide Fragments ; tau Proteins
Language	English
Publishing date	2023-11-22
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural
ZDB-ID	207147-2
ISSN	1526-632X ; 0028-3878
ISSN (online)	1526-632X
ISSN	0028-3878
DOI	10.1212/WNL.0000000000200953
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ui II Zs.153: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MG 18: Show issues
Zs.MO 374: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Walking energetics and white matter hyperintensities in mid-to-late adulthood.

Dougherty, Ryan J / Wanigatunga, Amal A / An, Yang / Tian, Qu / Simonsick, Eleanor M / Albert, Marilyn S / Resnick, Susan M / Schrack, Jennifer A

Alzheimer's & dementia (Amsterdam, Netherlands)

2023 Volume 15, Issue 4, Page(s) e12501

Abstract: Introduction: White matter hyperintensities (WMHs) increase with age and contribute to cognitive and motor function decline. Energy costs for mobility worsen with age, as the energetic cost of walking increases and energetic capacity declines. We ... ...

Abstract	Introduction: White matter hyperintensities (WMHs) increase with age and contribute to cognitive and motor function decline. Energy costs for mobility worsen with age, as the energetic cost of walking increases and energetic capacity declines. We examined the cross-sectional associations of multiple measures of walking energetics with WMHs in mid- to late-aged adults. Methods: A total of 601 cognitively unimpaired adults (mean age 66.9 ± 15.3 years, 54% women) underwent brain magnetic resonance imaging scans and completed standardized slow- and peak-paced walking assessments with metabolic measurement (V̇O Results: Lower slow-paced V̇O Discussion: The cost-to-capacity ratio, which describes the percentage of capacity required for ambulation, was the walking energetic measure most strongly associated with WMHs.
Language	English
Publishing date	2023-11-14
Publishing country	United States
Document type	Journal Article
ZDB-ID	2832898-X
ISSN	2352-8729
ISSN	2352-8729
DOI	10.1002/dad2.12501
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Changes in cognition.

Albert, Marilyn S

Neurobiology of aging

2011 Volume 32 Suppl 1, Page(s) S58–63

Abstract: The clinical hallmark of Alzheimer's disease (AD) is a gradual decline in cognitive function. For the majority of patients the initial symptom is an impairment in episodic memory, i.e., the ability to learn and retain new information. This is followed by ...

Abstract	The clinical hallmark of Alzheimer's disease (AD) is a gradual decline in cognitive function. For the majority of patients the initial symptom is an impairment in episodic memory, i.e., the ability to learn and retain new information. This is followed by impairments in other cognitive domains (e.g., executive function, language, spatial ability). This impairment in episodic memory is evident among individuals with mild cognitive impairment (MCI) and can be used to predict likelihood of progression to dementia, particularly in association with AD biomarkers. Additionally, cognitively normal individuals who are likely to progress to mild impairment tend to perform more poorly on tests of episodic memory than do those who remain stable. This cognitive presentation is consistent with the pathology of AD, showing neuronal loss in medial temporal lobe structures essential for normal memory. Similarly, there are correlations between magnetic resonance imaging (MRI) measures of medial temporal lobe structures and memory performance among individuals with mild cognitive impairment. There are recent reports that amyloid accumulation may also be associated with memory performance in cognitively normal individuals.
MeSH term(s)	Alzheimer Disease/diagnosis ; Alzheimer Disease/pathology ; Alzheimer Disease/psychology ; Biomarkers ; Brain/pathology ; Brain/physiopathology ; Cognition ; Cognitive Dysfunction/diagnosis ; Cognitive Dysfunction/pathology ; Cognitive Dysfunction/psychology ; Humans ; Magnetic Resonance Imaging ; Risk
Chemical Substances	Biomarkers
Language	English
Publishing date	2011-11-12
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	604505-4
ISSN	1558-1497 ; 0197-4580
ISSN (online)	1558-1497
ISSN	0197-4580
DOI	10.1016/j.neurobiolaging.2011.09.010
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1685: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MG 10: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Early amygdala and ERC atrophy linked to 3D reconstruction of rostral neurofibrillary tau tangle pathology in Alzheimer's disease.

Stouffer, Kaitlin M / Chen, Claire / Kulason, Sue / Xu, Eileen / Witter, Menno P / Ceritoglu, Can / Albert, Marilyn S / Mori, Susumu / Troncoso, Juan / Tward, Daniel J / Miller, Michael I

NeuroImage. Clinical

2023 Volume 38, Page(s) 103374

Abstract: Previous research has emphasized the unique impact of Alzheimer's Disease (AD) pathology on the medial temporal lobe (MTL), a reflection that tau pathology is particularly striking in the entorhinal and transentorhinal cortex (ERC, TEC) early in the ... ...

Abstract	Previous research has emphasized the unique impact of Alzheimer's Disease (AD) pathology on the medial temporal lobe (MTL), a reflection that tau pathology is particularly striking in the entorhinal and transentorhinal cortex (ERC, TEC) early in the course of disease. However, other brain regions are affected by AD pathology during its early phases. Here, we use longitudinal diffeomorphometry to measure the atrophy rate from MRI of the amygdala compared with that in the ERC and TEC in cognitively unimpaired (CU) controls, CU individuals who progressed to mild cognitive impairment (MCI), and individuals with MCI who progressed to dementia of the AD type (DAT), using a dataset from the Alzheimer's Disease Neuroimaging Initiative (ADNI). Our results show significantly higher atrophy rates of the amygdala in both groups of 'converters' (CU→MCI, MCI→DAT) compared to controls, with rates of volume loss comparable to rates of thickness loss in the ERC and TEC. We localize atrophy within the amygdala within each of these groups using fixed effects modeling. Controlling for the familywise error rate highlights the medial regions of the amygdala as those with significantly higher atrophy in both groups of converters than in controls. Using our recently developed method, referred to as Projective LDDMM, we map measures of neurofibrillary tau tangles (NFTs) from digital pathology to MRI atlases and reconstruct dense 3D spatial distributions of NFT density within regions of the MTL. The distribution of NFTs is consistent with the spatial distribution of MR measured atrophy rates, revealing high densities (and atrophy) in the amygdala (particularly medial), ERC, and rostral third of the MTL. The similarity of the location of NFTs in AD and shape changes in a well-defined clinical population suggests that amygdalar atrophy rate, as measured through MRI may be a viable biomarker for AD.
MeSH term(s)	Humans ; Alzheimer Disease/diagnostic imaging ; Alzheimer Disease/pathology ; Imaging, Three-Dimensional ; Temporal Lobe/pathology ; Amygdala/diagnostic imaging ; Amygdala/pathology ; Magnetic Resonance Imaging ; Atrophy/pathology ; Cognitive Dysfunction/diagnostic imaging ; Cognitive Dysfunction/pathology
Language	English
Publishing date	2023-03-15
Publishing country	Netherlands
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, Non-P.H.S.
ZDB-ID	2701571-3
ISSN	2213-1582 ; 2213-1582
ISSN (online)	2213-1582
ISSN	2213-1582
DOI	10.1016/j.nicl.2023.103374
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Changing the trajectory of cognitive decline?

Albert, Marilyn S

The New England journal of medicine

2007 Volume 357, Issue 5, Page(s) 502–503

MeSH term(s)	Alzheimer Disease/physiopathology ; Alzheimer Disease/psychology ; Animals ; Chromatin Assembly and Disassembly ; Disease Models, Animal ; Environment ; Histone Deacetylase Inhibitors ; Histone Deacetylases/metabolism ; Humans ; Learning/physiology ; Memory/drug effects ; Memory/physiology ; Mice
Chemical Substances	Histone Deacetylase Inhibitors ; Histone Deacetylases (EC 3.5.1.98)
Language	English
Publishing date	2007-08-02
Publishing country	United States
Document type	Journal Article
ZDB-ID	207154-x
ISSN	1533-4406 ; 0028-4793
ISSN (online)	1533-4406
ISSN	0028-4793
DOI	10.1056/NEJMcibr073273
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.34: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Inter-library loan at ZB MED

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito